Primary Cutaneous Mucinous Carcinoma
Primary cutaneous mucinous carcinoma (PCMC) is a rare low-grade adnexal carcinoma characterized by tumor cells floating in pools of extracellular mucin. It most commonly presents as a slow-growing pink-erythematous nodule on the periorbital region or head and neck in older adults. Histologically, the defining feature is nests of epithelial cells within lakes of mucinous material separated by fibrovascular septa. Immunohistochemistry (CK7+, CK20−) distinguishes PCMC from metastatic mucinous adenocarcinoma of gastrointestinal origin (CK20+); synaptophysin and chromogranin positivity is seen in the neuroendocrine subtype only. Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is recognized as the in situ precursor of neuroendocrine-type PCMC. Treatment involves surgical excision with margin control, and Mohs micrographic surgery is particularly advantageous for periorbital tumors where tissue conservation is critical. Overall prognosis is favorable, with a distant metastasis rate of approximately 5–6% and a 9% risk of subsequent primary malignancy at another site.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-03-13·Updated: 2026-03-13·Reviewed: 2026-03-13
mucinous carcinomaprimary cutaneous mucinous carcinomaPCMCendocrine mucin-producing sweat gland carcinomaEMPSGCadnexal carcinomaperiorbital tumoreyelid cancerCK7CK20synaptophysinchromograninMohs surgeryrare skin cancermucinous adenocarcinomaBerEP4
Key Takeaways
- PCMC is a rare adnexal carcinoma characterized by tumor cells floating in mucin pools, most commonly affecting the periorbital region.
- CK20 negativity with CK7 positivity distinguishes primary cutaneous from metastatic gastrointestinal mucinous carcinoma.
- EMPSGC (endocrine mucin-producing sweat gland carcinoma) is the recognized in situ precursor of neuroendocrine-type PCMC and carries a more favorable prognosis.
- Mohs surgery is preferred for periorbital tumors due to tissue conservation needs and the higher metastatic risk at this site.
- Approximately 9% of patients with PCMC develop a subsequent primary malignancy, necessitating ongoing cancer surveillance.
Overview
Primary cutaneous mucinous carcinoma (PCMC) is a rare sweat gland-derived adnexal malignancy. It accounts for less than 0.01% of all cutaneous malignancies, with an age-adjusted incidence of approximately 0.04 per 100,000 person-years. PCMC typically presents in the 6th–7th decade as a slow-growing, painless, pink-erythematous or translucent nodule. The periorbital/eyelid region is the single most common site, followed by other head and neck locations. A critical distinction must be made between primary cutaneous disease and cutaneous metastasis from an internal mucinous adenocarcinoma (particularly colorectal or breast), as the treatment and prognosis differ substantially.
Clinical Features
PCMC presents as a pink, erythematous, or skin-colored nodule or papule, often with a smooth or slightly translucent surface. Growth is typically indolent, often present for months to years before diagnosis. The periorbital region is the most frequent location, with other head and neck sites also common. Unlike many other rare cutaneous malignancies, PCMC may occur more frequently in Black patients than previously recognized.
Anatomical Distribution
Eyelid and periorbital tumors constitute the largest single-site group. Other reported sites include cheeks, scalp, trunk, and extremities. Eyelid tumors carry a higher rate of distant metastasis (~15%) compared to other sites, possibly reflecting delayed diagnosis in this location.
Risk Factors
Peak incidence occurs at age 40–80 years (most common in the 6th–7th decade). The pathogenesis remains incompletely understood, though the recognized precursor lesion, endocrine mucin-producing sweat gland carcinoma (EMPSGC), suggests an eccrine/apocrine origin with neuroendocrine differentiation.
Histopathology & Immunohistochemistry
The hallmark histologic feature is nests and islands of epithelial cells floating within large pools of extracellular mucinous material, separated by thin fibrovascular septa. Two subtypes are recognized based on neuroendocrine differentiation.
Neuroendocrine Type (EMPSGC-Associated)
The neuroendocrine subtype arises from EMPSGC (endocrine mucin-producing sweat gland carcinoma), which is considered its in situ precursor. EMPSGC is found coexisting with invasive PCMC in approximately 36% of cases. The neuroendocrine subtype carries a significantly lower recurrence rate (~12%) compared to the non-neuroendocrine subtype (~30%), and distant metastasis is exceedingly rare.
Non-Neuroendocrine Type
The non-neuroendocrine subtype lacks expression of synaptophysin and chromogranin. It demonstrates higher recurrence rates (up to 30%) and lymph node metastasis rates (~11%) compared to the neuroendocrine type.
Immunohistochemistry Panel
The IHC panel serves two purposes: confirming the diagnosis and, critically, distinguishing primary cutaneous from metastatic mucinous adenocarcinoma.
| Marker | PCMC | GI Metastasis | Breast Metastasis |
|---|---|---|---|
| CK7 | Positive | Variable | Positive |
| CK20 | Negative | Positive | Negative |
| BerEP4 | Positive | Variable | Variable |
| EMA | Positive | Positive | Positive |
| pCEA | Positive | Positive | Positive |
| Synaptophysin | Positive (NE type) | Negative | Negative |
| Chromogranin | Positive (NE type) | Negative | Negative |
| CDX2 | Negative | Positive | Negative |
| ER/PR | Variable | Negative | Positive |
Staging & Workup
No validated consensus staging system exists specifically for PCMC. Staging follows the general AJCC cutaneous carcinoma framework when applicable. The initial workup should exclude a non-cutaneous primary:
Recommended Workup
Age-appropriate cancer screening should be performed in all patients diagnosed with PCMC to exclude secondary (metastatic) disease. Particular attention to colorectal, breast, and genitourinary malignancies is warranted. Sentinel lymph node biopsy is not routinely recommended but may be considered for large or deeply invasive tumors, particularly those in the eyelid region where metastatic rates are higher.
Treatment
Surgical excision with clear margins is the standard of care for PCMC.
Mohs Micrographic Surgery
Mohs surgery is particularly well-suited for periorbital PCMC, where tissue conservation is paramount and local recurrence rates after conventional excision can reach 30%. The ability to examine 100% of the margin in real time is especially valuable given the frequent periocular location of these tumors.
Wide Local Excision
Standard excision with adequate margins (typically 1–2 cm) may be appropriate for truncal or extremity tumors where tissue conservation is less critical. Margin assessment by permanent sections is recommended.
Advanced Disease
Systemic therapy options for metastatic PCMC are not well-established due to the rarity of advanced disease. No consensus chemotherapy regimen exists. Radiation therapy may be considered for unresectable or recurrent tumors.
Prognosis & Surveillance
Overall prognosis for PCMC is favorable compared to other rare cutaneous malignancies.
Prognosis by Subtype and Location
PCMC-specific mortality is low overall. However, eyelid tumors carry a higher distant metastasis rate (~15%) compared to other sites.
| Parameter | Value |
|---|---|
| Overall distant metastasis rate | 5–6% |
| Eyelid distant metastasis rate | ~15% |
| Local recurrence (non-NE type) | ~30% |
| Local recurrence (NE/EMPSGC type) | ~12% |
| Lymph node metastasis (non-NE type) | ~11% |
| Subsequent primary malignancy risk | ~9% |
| Most common distant metastasis sites | Lung, lymph nodes, skin |
Surveillance Strategy
Clinical examination every 6 months for the first 3 years, then annually. Complete skin and lymph node examination at each visit. Age-appropriate cancer screening at regular intervals given the 9% risk of subsequent primary malignancy at other sites.
Frequently Asked Questions
Related Articles
Extramammary Paget Disease (EMPD): Mohs Indications & TreatmentSebaceous Carcinoma: Mohs Indications & TreatmentMicrocystic Adnexal Carcinoma (MAC): Mohs Indications & TreatmentMohs Micrographic Surgery TechniqueMohs Lab: Tissue Processing & Frozen Section HistologyTumor Biology & Molecular Pathways in Cutaneous Oncology
References
- [1]Rismiller K, Knackstedt TJ. Incidence and Survival of Primary Cutaneous Mucinous Carcinoma of the Skin: A SEER Analysis. J Am Acad Dermatol. 2020. doi:10.1016/j.jaad.2019.10.078 PMID: 31702595
- [2]Au JH, Iyengar S, Engelman DE, Kazlouskaya V. Endocrine mucin-producing sweat gland carcinoma and primary cutaneous mucinous carcinoma: a review. J Cutan Pathol. 2021. doi:10.1111/cup.13987 PMID: 33590507
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program